Abstract 60P
Background
Ivosidenib (IVO) has demonstrated efficacy as an oral inhibitor of the protein encoded by the mutant isocitrate dehydrogenase 1 (mIDH1) gene in patients (pts) with cholangiocarcinoma (CCA) in the phase 3 ClarIDHy study. To further consolidate safety and efficacy data of IVO in the real world, the ProvIDHe study was initiated. The study is in a setting similar to daily practice, enabling access to treatment with IVO for pts with CCA.
Methods
Adult pts with locally advanced or metastatic mIDH1CCA who had received at least one prior line of systemic treatment are eligible for inclusion in this international, single-arm phase 3b study. Pts receive 500 mg IVO orally once daily and continue treatment as long as clinical benefit is observed, until unacceptable toxicity, or until IVO is accessible via medical prescription. The primary endpoint of the study is safety. Baseline characteristics and molecular testing outcomes are presented here.
Results
As of the cut-off date of 9 February 2024, 158 pts from 10 countries were enrolled. 131 pts were included in the safety analysis set. Baseline characteristics are presented (Table). Most pts were 2
CCA, Cholangiocarcinoma; ECOG PS, eastern cooperative oncology group performance score ‡Unless otherwise stated, *n=131, 25 pts did not receive prior therapy in this setting
Conclusions
This first interim analysis focused on baseline characteristics of pts enrolled in the ProvIDHe study, including previous treatment regimens for advanced/metastatic disease and molecular testing. The study is still enrolling, and future analyses will focus on patient outcomes.
Clinical trial identification
NCT05876754.
Editorial acknowledgement
Editorial assistance was provided by Emily Eagles of Empowering Strategic Performance Ltd.
Legal entity responsible for the study
Servier.
Funding
Servier.
Disclosure
L. Rimassa: Financial Interests, Advisory Role: AbbVie, AstraZeneca, Basilea, Bayer, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Other, Honoraria/lectures: AstraZeneca, Bayer, BMS, Guerbet, Incyte, Ipsen, Roche, Servier; Financial Interests, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Research Funding: Agios, AstraZeneca, BeiGene, Eisai, Exelixis, FibroGen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Zymeworks. J.A. Bridgewater: Financial Interests, Other, Speaker's Fee's: Incyte, Servier; Financial Interests, Other, Consultancy: BMS, Roche, Bayer, AstraZeneca, Incyte, Taiho, Basilea; Financial Interests, Research Funding: Incyte. A. Casadei Gardini: Financial Interests, Other, consulting fees: AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, IQVIA, MSD, Roche, Servier; Financial Interests, Other, lecture fees: AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Roche, Servier; Financial Interests, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca, Eisai. H. Wilmink: Financial Interests, Other, Consultancy: AstraZeneca, MSD, Servier; Financial Interests, Institutional, Research Funding: Servier, MSD, Nordic. H. Sim: Financial Interests, Other, Honoraria: Eli Lilly, Servier; Financial Interests, Institutional, Research Funding: AbbVie, Bristol Myers Squibb. J. de Vos-Geelen: Financial Interests, Institutional, Research Grant: Servier. T. Macarulla Mercade: Financial Interests, Personal, Advisory Board: Ability Pharmaceutical, SL, AstraZeneca, Basilea Pharma, Baxter, BioLineRx Ltd., Celgene SLU, Eisai, Ipsen Pharma, Incyte; Financial Interests, Personal, Other, Direct research fund: Servier, Merck, Sharp & Dohme, Novocure, QED Therapeutics Inc., Roche, Sanofi-Aventis, Zymeworks; Financial Interests, Personal, Invited Speaker: Lilly, Janssen; Financial Interests, Institutional, Research Grant: Amc Medical Research, Armo Biosciences, Basilea, Biokeralty Research Institute, Merck Sharp & Dohme, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, AbbVie Farmaceútica, Ability Pharmaceuticals, Agios, Amgen, Aslan, AstraZeneca, Bayer, BeiGene, BioLineRx, Blueprint Medicines, Boston Biomedical, Bristol Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-La Roche, FibroGen, Genentech, Hallozyme, Immunomedics, Incyte, Ipsen, Lab. Menarini, Lilly, Loxo Oncology, MedImmune, Merrimack, Millenium, Nelum, Novartis, Novocure, Pfizer, Pharmacyclics, Roche, Zymeworks; Non-Financial Interests, Member: American Society of Clinical Oncology - ASCO, “Sociedad Española de Oncología Médica” – SEOM, Sociedad Europea de Oncología Médica - ESMO; Other, Editorial Board: GI Annals of Oncology. D. Malka: Financial Interests, Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Incyte, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Taiho, Viatris; Financial Interests, Other, Honoraria for lectures, presentations, or educational events: Amgen, AstraZeneca, Bayer, BMS, Foundation Medicine, Incyte, Leo Pharma, Medscape, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Veracyte, Viatris; Financial Interests, Other, Support for attending meetings and/or travel: Amgen, Bayer, BMS, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Viatris. H. Gharbi, R. Robert, A. Sullivan: Financial Interests, Full or part-time Employment: Servier. A. Vogel: Financial Interests, Advisory Role: AbbVie, AstraZeneca, Amgen, BeiGene, Boehringer Mannheim, BMS, Eisai, Incyte, MSD, Pierre Fabre, Roche, Servier, Taiho.
Resources from the same session
1998P - Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC)
Presenter: Dingwei Ye
Session: Poster session 13
1999P - Expression heterogeneity of ADC-related targets between primary tumors and metastatic lymph nodes in advanced urothelial cancers
Presenter: Xingliang Tan
Session: Poster session 13
2001P - Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study
Presenter: Florence Joly Lobbedez
Session: Poster session 13
2002P - Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study
Presenter: Luzhe Yan
Session: Poster session 13
2003P - Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
Presenter: Michal Sternschuss
Session: Poster session 13
2004P - The combination of high levels of serum cytokeratin fragment 21-1 and VI-RADS≧4 has diagnostic and prognostic value in high-stage bladder cancer
Presenter: Shunsuke Ikuma
Session: Poster session 13
2005P - Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma
Presenter: Alvaro Pinto Marin
Session: Poster session 13
2006P - Prognostic factors in metastatic urothelial cancer (mUC): Developing an accessible model for predicting patient survival
Presenter: Sevinc Balli
Session: Poster session 13
2007P - Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials
Presenter: Dag Rune Stormoen
Session: Poster session 13